NEW YORK, February 6, 2024 - Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track …

Aug 15, 2024 · Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in …

Mar 11, 2025 · The Phase 3 VERITAC-2 clinical trial (NCT05654623) is a global randomized study evaluating the efficacy and safety of vepdegestrant (ARV-471) as a monotherapy …

May 31, 2023 · The randomized phase 3 VERITAC-2 study (NCT05654623) will compare efficacy and safety of ARV-471 vs the SERD fulvestrant in patients with ER+/HER2- advanced breast …

Mar 12, 2025 · The structure of ARV-471 is shown at right. The left-hand site is a ligand for the estrogen receptor alpha protein (ER-alpha), then there's a piperidine-based lined over to an …

The et al. Enhanced efficacy of vepdegestrant (ARV 471), a novel PROTAC® estrogen receptor degrader, in combination with targeted agents in ER+ breast cancer models. AACR 2023; …

• ARV-471 is in development for the treatment of women with ER+ locally advanced or metastatic breast cancer • Potential as both a single agent and in combination with CDK4/6

Aug 15, 2024 · Vepdegestrant (ARV-471) is a potent, selective, orally bioavailable PROTAC small molecule that simultaneously binds the intracellular E3 ligase cereblon (CRBN) and the ligand …

Background: ARV-471 is a novel, potent, orally bioavailable PROteolysis TArgeting Chimera (PROTAC) protein degrader that selectively targets the ER. In xenograft models, ARV-471 …

Gough SM, et al. Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway …